A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD
NCT00280371 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 345
Last updated 2010-11-11
Summary
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
Conditions
Interventions
- DRUG
-
Formoterol Fumarate
Sponsors & Collaborators
-
Dey
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-01-31
- Primary Completion
- 2006-07-31
- Completion
- 2007-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
NCT01488019 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01168310 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01437540 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)
NCT00383721 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
NCT00774761 ·Status: COMPLETED ·Phase: PHASE2
-
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
NCT00742248 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Patients With COPD
NCT00215384 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Patients With COPD
NCT00215423 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
NCT01043601 ·Status: WITHDRAWN ·Phase: PHASE2
-
Budesonide / Formoterol in Treatment of Exacerbations of COPD
NCT00239278 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Subjects Greater Than 40 Years of Age With COPD
NCT00507234 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
NCT00403286 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01437397 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00064415 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
NCT01113593 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
NCT03022097 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
NCT00628862 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00691405 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00706914 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02196077 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT03276078 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00929708 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360 ·Status: COMPLETED ·Phase: PHASE2